



**Ref: SEC/SE/2026-27**

**Date: June 01, 2026**

To,  
Corporate Relations Department  
**BSE Ltd.**  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai- 400001

Listing Department  
**National Stock Exchange of India Ltd.**  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/1, G Block, Bandra Kurla Complex  
Bandra (E), Mumbai – 400051

BSE Scrip Code: 500096

NSE Scrip Symbol: DABUR

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”): Clarification /Confirmation on news item appearing in “Media/Publication”**

**Sub: Recent news item which appeared in the mainstream media/publication dated May 29, 2026 and May 30, 2026 captioned “U.S. drug regulator flags data integrity, maintenance lapses at Dabur India plant”**

Dear Sir/Madam,

Pursuant to provisions of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), as amended and in reference to above cited subject and the news appearing in various mainstream media/publication dated May 29, 2026 and May 30, 2026, we hereby provide the following clarification on the aforesaid news item:

The observations provided by United States Food & Drug Administration (“USFDA”) concerns only a small part of our manufacturing plant situated at Silvassa, Dadra and Nagar Haveli, which generates insignificant revenue for the Company. The aforesaid plant continues to be operational. We are actively engaged with the USFDA on the findings of the audit and have built a robust corrective and preventive action plan to resolve the concerns raised, which has been shared with the USFDA with updates on the progress being shared regularly. We continue to implement strong controls to ensure that our quality systems are never compromised. We are committed for maintaining the highest standards of product quality in our manufacturing operations at all our sites and ensuring optimal consumer experience.

We would like to reiterate our unwavering commitment to quality, safety, and compliance across all our products and manufacturing operations. We would like to assure that all our products are manufactured and delivered with highest level of quality and hygiene, which is in strict compliance with applicable regulations, standards and specifications. Also, we constantly leverage our extensive Global Research and Development network for enhancement of quality standards for our products.

As of now, there is no impact on financial, operation or other activities of the Company due to the above. Further, there is no other material event/ information that requires disclosure under Regulation 30 of the SEBI Listing Regulations, 2015.

The Company is committed to comply with the regulatory requirements and will make appropriate disclosures in accordance with the applicable laws.

The above information shall also be made available on the Company's website at [www.dabur.com](http://www.dabur.com).

This is for your information and records.

Thanking you,

Yours faithfully  
For **Dabur India Limited**

**(Ashok Kumar Jain)**  
**Group Company Secretary and Chief Compliance Officer**